Related Experiment Video
Updated: Dec 14, 2025
07:49
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
11.8K
Pharmacological agents in development for diabetic macular edema
Mohammad Ali Sadiq1, Muhammad Sohail Halim2,3, Muhammad Hassan2
1Department of Ophthalmology, University of Louisville, Louisville, KY USA.
International Journal of Retina and Vitreous
|July 17, 2020
Summary
Newer therapies for diabetic macular edema (DME) show promise beyond current anti-VEGF treatments. These novel agents may offer safer and more effective options for visual loss in diabetic retinopathy patients.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Diabetic macular edema (DME) is a primary cause of vision loss in diabetic retinopathy.
- Anti-vascular endothelial growth factor (anti-VEGF) therapy revolutionized DME treatment but has limitations like frequent injections, high costs, and variable responses.
- These limitations drive the search for novel therapeutic agents.
Purpose of the Study:
- To review novel treatment agents for DME.
- To discuss agents targeting various pathways, including monotherapy and combination approaches.
Main Methods:
- Focus on investigational drugs for DME management.
- Discussion of novel anti-VEGF inhibitors, TIE-2 receptor modulators, integrin peptide inhibitors, and rho kinase inhibitors.
- Exploration of future therapies like neuroprotection and gene therapy.
Main Results:
- Early clinical trials suggest newer agents are potentially safe and efficacious for DME.
- These novel agents aim to overcome limitations of current therapies.
Conclusions:
- Investigational pharmacological therapies for DME present a promising future.
- Further data from large clinical trials are necessary before widespread clinical adoption.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
869
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
869
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
438
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
438
01:23Dipeptidyl Peptidase 4 Inhibitors
448
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
448
01:28Angle Closure Glaucoma: Treatment
1.0K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K
01:24Glucagon-like Receptor Agonists
710
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
710
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
511
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
511